No matches
Pulmonology

Worsening Disease Results in a Vicious Cycle of COPD

Uncover the complex interconnected factors that drive the progressive and worsening vicious cycle of COPD.

Related resources

Eosinophils as a Biomarker for Type 2 Asthma

Eosinophils as a Biomarker for Type 2 Asthma

expert video
Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

expert video
FeNO as a Biomarker for Type 2 Asthma

FeNO as a Biomarker for Type 2 Asthma

expert video
IgE as a Biomarker for Type 2 Asthma

IgE as a Biomarker for Type 2 Asthma

expert video
What Differentiates COPD Exacerbations From Asthma Exacerbations?

What Differentiates COPD Exacerbations From Asthma Exacerbations?

expert video
Clinical Manifestations Associated With Airway Remodeling in Asthma

Clinical Manifestations Associated With Airway Remodeling in Asthma

expert video
Impact of Exacerbations in COPD

Impact of Exacerbations in COPD

expert video
Exacerbations Lead to Worsening Lung Function

Exacerbations Lead to Worsening Lung Function

expert video
Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma

Unraveling the Link of Type 2 Inflammation and Airway Remodeling in Asthma

expert video
Mucus Plugging as a Potential Target in Asthma Management

Mucus Plugging as a Potential Target in Asthma Management

expert video
Multifaceted Role of IL-13 in Airway Remodeling

Multifaceted Role of IL-13 in Airway Remodeling

expert video
Pediatric Asthma Trajectory and Clinical Remission

Pediatric Asthma Trajectory and Clinical Remission

expert video
Screen depicting a mucus plug in the airways

A view into the Airway: The Pathophysiology and Clinical Relevance of Mucus Plugs in Asthma

videoanimation
Compounded Burden of Co-existing Type 2 Airway Diseases

Compounded Burden of Co-existing Type 2 Airway Diseases

expert video
Spotlight on Type 2 Inflammation in the Upper and Lower Airways

Spotlight on Type 2 Inflammation in the Upper and Lower Airways

expert video
The Cycle of Inflammation in Adult Asthma

The Cycle of Inflammation in Adult Asthma

interactivity
ADVENT On Air | Disease Modification in Severe Asthma: Framework, Assessment, and Clinical Impact

ADVENT On Air | Disease Modification in Severe Asthma: Framework, Assessment, and Clinical Impact

Podcast
ADVENT On Air | Breath, Blood, and Beyond: The Prognostic Power of Biomarkers in Asthma Across Ages

ADVENT On Air | Breath, Blood, and Beyond: The Prognostic Power of Biomarkers in Asthma Across Ages

Podcast
The Weight of Breath: The Impact of Pediatric Asthma on Patients and Caregivers

The Weight of Breath: The Impact of Pediatric Asthma on Patients and Caregivers

videoanimation
FeNO Is a Noninvasive Biomarker That Can Support Diagnosis and Management for Asthma Patients

FeNO Is a Noninvasive Biomarker That Can Support Diagnosis and Management for Asthma Patients

Infographic
Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation

Airway Hyperresponsiveness In Asthma Is Mainly Driven By Components Of Type 2 Inflammation

interactivity
Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video

Pathways to Disease: Inflammation in Chronic Obstructive Pulmonary Disease Video

videoanimation
The Burden in Patients with CRSwNP and Coexisting Asthma

The Burden in Patients with CRSwNP and Coexisting Asthma

expert video
Low Disease Activity and Disease Stability: Setting New Goals for COPD Care

Low Disease Activity and Disease Stability: Setting New Goals for COPD Care

Infographic
ERS 2025 | Type 2 Severe Asthma "Unplugged": Reducing Mucus to Improve Long-term Patient Outcomes

ERS 2025 | Type 2 Severe Asthma "Unplugged": Reducing Mucus to Improve Long-term Patient Outcomes

videoanimation
Pathways Driving Chronic Airway Remodeling in Asthma

Pathways Driving Chronic Airway Remodeling in Asthma

videoanimation
CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma

CRSwNP at Center Stage: Impact of Biologics in Patients with Co-existing Type 2 Asthma

expert video
Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

Chronic Obstructive Pulmonary Disease: Disease Burden & Heterogeneity

interactivity
COPD and Asthma: What's the Difference and Is There a Link?

COPD and Asthma: What's the Difference and Is There a Link?

interactivity
2025 ADVENT Forum | Latest Clinical Data from the COPD Biologic Treatment Landscape

2025 ADVENT Forum | Latest Clinical Data from the COPD Biologic Treatment Landscape

expert video

Learning objectives

  • Discover the complex factors that contribute to the progressive nature of COPD
  • Investigate the complex interplay of elements driving worsening symptoms and health decline in COPD

Description

Explore how initiating factors, chronic airway inflammation, and structural changes interact with symptoms and exacerbations in COPD. This ongoing interplay drives disease progression, contributing to further lung damage and health deterioration over time.

Tags
exacerbationschronic inflammationdisease progressionsymptomsquality of life
MAT-GLB-2506222 - 2.0 - 04/2026

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2026 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 - 4.0 - 10/2025

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: GreeceChange country/region